Patents by Inventor Mark David Charles
Mark David Charles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11766434Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.Type: GrantFiled: April 29, 2021Date of Patent: September 26, 2023Assignee: Cancer Research Technology LimitedInventors: Emma L. Carswell, Mark David Charles, Chukuemeka Tennyson Ekwuru, Frederic Elustondo, Katherine M. Fowler, Gregory R. Ott, Jonathan R. Roffey, Joanna L. Brookfield, Daniel James Ford, Mathew L. Calder
-
Patent number: 11753405Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 1,2,4-triazin-3-yl, pyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R1 can be hydrogen, methoxy, trifluoromethoxy, oxetan-3-yl, 3-fluoroazetidin-1-yl, 3-methoxyazetidin-1-yl, or 3,3-difluoroazetidin-1-yl; R2 can be hydrogen or fluoro; R3 can be hydrogen or methoxy; and R4 can be methoxy, ethoxy, or methoxymethyl; provided that when R1 is hydrogen, methoxy or trifluoromethoxy, then R3 is not hydrogen, and/or R4 is methoxymethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.Type: GrantFiled: April 15, 2021Date of Patent: September 12, 2023Assignee: Cancer Research Technology LimitedInventors: Johannes Wilhelmus Maria Nissink, Maurice Raymond Verschoyle Finlay, Mark David Charles
-
Publication number: 20220079942Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.Type: ApplicationFiled: April 29, 2021Publication date: March 17, 2022Inventors: Emma L. Carswell, Mark David Charles, Chukuemeka Tennyson Ekwuru, Frederic Elustondo, Katherine M. Fowler, Gregory R. Ott, Jonathan R. Roffey, Joanna L. Brookfield, Daniel James Ford, Mathew L. Calder
-
Publication number: 20210246131Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 1,2,4-triazin-3-yl, pyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R1 can be hydrogen, methoxy, trifluoromethoxy, oxetan-3-yl, 3-fluoroazetidin-1-yl, 3-methoxyazetidin-1-yl, or 3,3-difluoroazetidin-1-yl; R2 can be hydrogen or fluoro; R3 can be hydrogen or methoxy; and R4 can be methoxy, ethoxy, or methoxymethyl; provided that when R1 is hydrogen, methoxy or trifluoromethoxy, then R3 is not hydrogen, and/or R4 is methoxymethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.Type: ApplicationFiled: April 15, 2021Publication date: August 12, 2021Inventors: Johannes Wilhelmus Maria Nissink, Maurice Raymond Verschoyle Finlay, Mark David Charles
-
Patent number: 11020396Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.Type: GrantFiled: November 7, 2017Date of Patent: June 1, 2021Assignee: Cancer Research Technology LimitedInventors: Emma L. Carswell, Mark David Charles, Chukuemeka Tennyson Ekwuru, Frederic Elustondo, Katherine M. Fowler, Gregory R. Ott, Jonathan R. Roffey, Joanna L. Brookfield, Daniel James Ford, Mathew L. Calder
-
Patent number: 10981904Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 1,2,4-triazin-3-yl, pyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R1 can be hydrogen, methoxy, trifluoromethoxy, oxetan-3-yl, 3-fluoroazetidin-1-yl, 3-methoxyazetidin-1-yl, or 3,3-difluoroazetidin-1-yl; R2 can be hydrogen or fluoro; R3 can be hydrogen or methoxy; and R4 can be methoxy, ethoxy, or methoxymethyl; provided that when R1 is hydrogen, methoxy or trifluoromethoxy, then R3 is not hydrogen, and/or R4 is methoxymethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.Type: GrantFiled: May 3, 2019Date of Patent: April 20, 2021Assignee: Cancer Research Technology LimitedInventors: Johannes Wilhelmus Maria Nissink, Maurice Raymond Verschoyle Finlay, Mark David Charles
-
Patent number: 10919896Abstract: The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: wherein X, R1, R2, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.Type: GrantFiled: September 22, 2017Date of Patent: February 16, 2021Assignee: Cancer Research Technology LimitedInventors: Emma L. Carswell, Mark David Charles, Anne Cochi, Benjamin J. Dugan, Chukuemeka Tennyson Ekwuru, Fred Elustondo, Katherine M. Fowler, Frederic Georges Marie Leroux, Nathaniel J. T. Monck, Gregory R. Ott, Jonathan R. Roffey, Gurwinder Sidhu, Neil Tremayne
-
Publication number: 20200123157Abstract: The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: wherein X, R1, R2, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.Type: ApplicationFiled: September 22, 2017Publication date: April 23, 2020Inventors: Emma L. Carswell, Mark David Charles, Anne Cochi, Benjamin J. Dugan, Chukuemeka Tennyson Ekwuru, Fred Elustondo, Katherine M. Fowler, Frederic Georges Marie Leroux, Nathaniel J.T. Monck, Gregory R. Ott, Jonathan R. Roffey, Gurwinder Sidhu, Neil Tremayne
-
Publication number: 20190389853Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 1,2,4-triazin-3-yl, pyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R1 can be hydrogen, methoxy, trifluoromethoxy, oxetan-3-yl, 3-fluoroazetidin-1-yl, 3-methoxyazetidin-1-yl, or 3,3-difluoroazetidin-1-yl; R2 can be hydrogen or fluoro; R3 can be hydrogen or methoxy; and R4 can be methoxy, ethoxy, or methoxymethyl; provided that when R1 is hydrogen, methoxy or trifluoromethoxy, then R3 is not hydrogen, and/or R4 is methoxymethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.Type: ApplicationFiled: May 3, 2019Publication date: December 26, 2019Inventors: Johannes Wilhelmus Maria Nissink, Maurice Raymond Verschoyle Finlay, Mark David Charles
-
Publication number: 20190336502Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.Type: ApplicationFiled: November 7, 2017Publication date: November 7, 2019Inventors: Emma L. Carswell, Mark David Charles, Chukuemeka Tennyson Ekwuru, Frederic Elustondo, Katherine M. Fowler, Gregory R. Ott, Jonathan R. Roffey, Joanna L. Brookfield, Daniel James Ford, Mathew L. Calder
-
Patent number: 10323028Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 1,2,4-triazin-3-yl, pyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R1 can be hydrogen, methoxy, trifluoromethoxy, oxetan-3-yl, 3-fluoroazetidin-1-yl, 3-methoxyazetidin-1-yl, or 3,3-difluoroazetidin-1-yl; R2 can be hydrogen or fluoro; R3 can be hydrogen or methoxy; and R4 can be methoxy, ethoxy, or methoxymethyl; provided that when R1 is hydrogen, methoxy or trifluoromethoxy, then R3 is not hydrogen, and/or R4 is methoxymethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.Type: GrantFiled: November 29, 2016Date of Patent: June 18, 2019Assignees: AstraZeneca AB, Cancer Research Technology LimitedInventors: Johannes Wilhelmus Maria Nissink, Maurice Raymond Verschoyle Finlay, Mark David Charles
-
Patent number: 10294221Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.Type: GrantFiled: July 2, 2018Date of Patent: May 21, 2019Assignees: AstraZeneca AB, Cancer Research Technology LimitedInventors: Maurice Raymond Verschoyle Finlay, Chukuemeka Tennyson Ekwuru, Mark David Charles, Piotr Antoni Raubo, Jonathan James Gordon Winter, Johannes Wilhelmus Maria Nissink
-
Publication number: 20180305349Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.Type: ApplicationFiled: July 2, 2018Publication date: October 25, 2018Inventors: Maurice Raymond Verschoyle Finlay, Chukuemeka Tennyson Ekwuru, Mark David Charles, Piotr Antoni Raubo, Jonathan James Gordon Winter, Johannes Wilhelmus Maria Nissink
-
Patent number: 10040788Abstract: The specification relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.Type: GrantFiled: May 27, 2015Date of Patent: August 7, 2018Assignees: AstraZeneca AB, Cancer Research Technology LimitedInventors: Maurice Raymond Verschoyle Finlay, Chukuemeka Tennyson Ekwuru, Mark David Charles, Piotr Antoni Raubo, Jonathan James Gordon Winter, Johannes Wilhelmus Maria Nissink
-
Patent number: 9938265Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 5-methylpyridazin-3-yl,5-chloropyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R can be hydrogen, fluoro, or methoxy; R1 can be hydrogen, methoxy, difluoromethoxy, or trifluoromethoxy; and R2 can be methyl or ethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.Type: GrantFiled: November 29, 2016Date of Patent: April 10, 2018Assignees: AstraZeneca AB, Cancer Research Technology LimitedInventors: Johannes Wilhelmus Maria Nissink, Maurice Raymond Verschoyle Finlay, Mark David Charles, Matt Wood
-
Publication number: 20170197954Abstract: The specification relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.Type: ApplicationFiled: May 27, 2015Publication date: July 13, 2017Applicants: AstraZeneca AB, Cancer Research Technology LimitedInventors: Maurice Raymond Verschoyle Finlay, Chukuemeka Tennyson Ekwuru, Mark David Charles, Piotr Antoni Raubo, Jonathan James Gordon Winter, Johannes Wilhelmus Maria Nissink
-
Publication number: 20170152254Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 5-methylpyridazin-3-yl, 5-chloropyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R can be hydrogen, fluoro, or methoxy; R1 can be hydrogen, methoxy, difluoromethoxy, or trifluoromethoxy; and R2 can be methyl or ethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.Type: ApplicationFiled: November 29, 2016Publication date: June 1, 2017Applicants: AstraZeneca AB, Cancer Research Technology LimitedInventors: Johannes Wilhelmus Maria Nissink, Maurice Raymond Verschoyle Finlay, Mark David Charles, Matt Wood
-
Publication number: 20170152255Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 1,2,4-triazin-3-yl, pyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R1 can be hydrogen, methoxy, trifluoromethoxy, oxetan-3-yl, 3-fluoroazetidin-1-yl, 3-methoxyazetidin-1-yl, or 3,3-difluoroazetidin-1-yl; R2 can be hydrogen or fluoro; R3 can be hydrogen or methoxy; and R4 can be methoxy, ethoxy, or methoxymethyl; provided that when R1 is hydrogen, methoxy or trifluoromethoxy, then R3 is not hydrogen, and/or R4 is methoxymethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.Type: ApplicationFiled: November 29, 2016Publication date: June 1, 2017Applicants: AstraZeneca AB, Cancer Research Technology LimitedInventors: Johannes Wilhelmus Maria Nissink, Maurice Raymond Verschoyle Finlay, Mark David Charles
-
Publication number: 20110098325Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyridine benzamide and pyrazine benzamide compounds (referred to herein as PDBA and PZBA compounds) which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.Type: ApplicationFiled: December 14, 2007Publication date: April 28, 2011Applicant: CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Tony Michael Raynham, Timothy Robin Hammonds, Mark David Charles, Grégoire Alexandre Pave, Caroline Heather Foxton, Wesley Peter Blackaby, Adrian Philip Stevens, Chukuemeka Tennyson Ekwuru
-
Publication number: 20090247519Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.Type: ApplicationFiled: April 26, 2007Publication date: October 1, 2009Inventors: Tony Michael Raynham, Timothy Robin Hammonds, Julia Helen Gilliatt, Mark David Charles, Gregoire Alexandre Pave, Caroline Heather Foxton, James Lindsay Carr, Neela Sumit Mistry